Amit P. Khandhar
Research Subjects
Amit P. Khandhar has a total of 251 co-authors. Here are the top co-authors by number of shared publications:
R. Matthew Ferguson
Lodespin Labs, LLC , Seattle, Washington 98103, United States
19 shared publications- Kannan M. Krishnan
Department of Materials Science and Engineering, 323 Roberts Hall, University of Washington, Seattle, Washington 98195, USA
18 shared publications Kannan M. Krishnan
Department of Materials Science and Engineering, University of Washington, Seattle, WA 98195
14 shared publicationsHamed Arami
Dep. Mater. Sci. Eng., Univ. Wash., Seattle, WA 98195, USA
11 shared publications- Patrick William Goodwill
Magnetic Insight Inc
10 shared publications Scott J. Kemp
Lodespin Labs, LLC , Seattle, Washington 98103, United States
8 shared publications
Latest Publications
- Open Access
- 12 November 2025
- Published by Springer Nature in Research Square
A localizing replicon RNA vaccine harnesses the intramuscular immune microenvironment to drive adaptive responses
Intramuscular administration of self-amplifying replicon RNA (repRNA) formulated with the cationic nanocarrier LION™ represents a promising strategy for inducing durable protective immunity with minimal doses and limited systemic reactogenicity. However, the cellular and molecular mechanisms by which it elicits adaptive immune responses remain incompletely understood. Here, we demonstrate that repRNA delivery generates a microenvironment within skeletal muscle that promotes adaptive immune responses. In this local environment, repRNA-transfected muscle cells transfer antigen-encoding RNA and proteins to antigen-presenting cells to cross-prime CD8⁺ T cells, while CD4⁺ T cells and CD138⁺ cells expand in parallel with antibody production. CD4⁺ T cells are required for humoral immunity, and intramuscular CD138⁺ cell frequencies correlate with serum antibody levels. These findings reveal a coordinated mechanism by which the muscle microenvironment orchestrates adaptive immunity following localized repRNA delivery and provide mechanistic insight for the rational design of next-generation RNA vaccines and therapeutics.
- 12 November 2025
- Published by Springer Nature in Research Square
Open AccessA localizing replicon RNA vaccine harnesses the intramuscular immune microenvironment to drive adaptive responses
Intramuscular administration of self-amplifying replicon RNA (repRNA) formulated with the cationic nanocarrier LION™ represents a promising strategy for inducing durable protective immunity with minimal doses and limited systemic reactogenicity. However, the cellular and molecular mechanisms by which it elicits adaptive immune responses remain incompletely understood. Here, we demonstrate that repRNA delivery generates a microenvironment within skeletal muscle that promotes adaptive immune responses. In this local environment, repRNA-transfected muscle cells transfer antigen-encoding RNA and proteins to antigen-presenting cells to cross-prime CD8⁺ T cells, while CD4⁺ T cells and CD138⁺ cells expand in parallel with antibody production. CD4⁺ T cells are required for humoral immunity, and intramuscular CD138⁺ cell frequencies correlate with serum antibody levels. These findings reveal a coordinated mechanism by which the muscle microenvironment orchestrates adaptive immunity following localized repRNA delivery and provide mechanistic insight for the rational design of next-generation RNA vaccines and therapeutics.
- Open Access
- 17 April 2025
- Published by BioInsights Publishing, Ltd. in Vaccine Insights
- Vol. 4 (2) , 75–76
Spotlight on RNA–LNP vaccine innovation
“These articles point to a future where precision, safety, and global equity define the next generation of mRNA vaccines.”
- 17 April 2025
- Published by BioInsights Publishing, Ltd. in Vaccine Insights
- Vol. 4 (2) , 75–76
Open AccessSpotlight on RNA–LNP vaccine innovation
“These articles point to a future where precision, safety, and global equity define the next generation of mRNA vaccines.”
- 17 November 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 377, 81-92
Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostability
- 17 November 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 377, 81-92
Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostability
- 7 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (759) , eadi1625
A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models
The recent emergence and rapid response to severe acute respiratory syndrome coronavirus 2 was enabled by prototype pathogen and vaccine platform approaches, driven by the preemptive application of RNA vaccine technology to the related Middle East respiratory syndrome coronavirus. Recently, the National Institutes of Allergy and Infectious Diseases identified nine virus families of concern, eight enveloped virus families and one nonenveloped virus family, for which vaccine generation is a priority. Although RNA vaccines have been described for a variety of enveloped viruses, a roadmap for their use against nonenveloped viruses is lacking. Enterovirus D68 was recently designated a prototype pathogen within the family Picornaviridae of nonenveloped viruses because of its rapid evolution and respiratory route of transmission, coupled with a lack of diverse anti-enterovirus vaccine approaches in development. Here, we describe a proof-of-concept approach using a clinical stage RNA vaccine platform that induced robust enterovirus D68–neutralizing antibody responses in mice and nonhuman primates and prevented upper and lower respiratory tract infections and neurological disease in mice. In addition, we used our platform to rapidly characterize the antigenic diversity within the six genotypes of enterovirus D68, providing the necessary data to inform multivalent vaccine compositions that can elicit optimal breadth of neutralizing responses. These results demonstrate that RNA vaccines can be used as tools in our pandemic-preparedness toolbox for nonenveloped viruses.
- 7 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (759) , eadi1625
A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models
The recent emergence and rapid response to severe acute respiratory syndrome coronavirus 2 was enabled by prototype pathogen and vaccine platform approaches, driven by the preemptive application of RNA vaccine technology to the related Middle East respiratory syndrome coronavirus. Recently, the National Institutes of Allergy and Infectious Diseases identified nine virus families of concern, eight enveloped virus families and one nonenveloped virus family, for which vaccine generation is a priority. Although RNA vaccines have been described for a variety of enveloped viruses, a roadmap for their use against nonenveloped viruses is lacking. Enterovirus D68 was recently designated a prototype pathogen within the family Picornaviridae of nonenveloped viruses because of its rapid evolution and respiratory route of transmission, coupled with a lack of diverse anti-enterovirus vaccine approaches in development. Here, we describe a proof-of-concept approach using a clinical stage RNA vaccine platform that induced robust enterovirus D68–neutralizing antibody responses in mice and nonhuman primates and prevented upper and lower respiratory tract infections and neurological disease in mice. In addition, we used our platform to rapidly characterize the antigenic diversity within the six genotypes of enterovirus D68, providing the necessary data to inform multivalent vaccine compositions that can elicit optimal breadth of neutralizing responses. These results demonstrate that RNA vaccines can be used as tools in our pandemic-preparedness toolbox for nonenveloped viruses.
- Open Access
- 24 March 2023
- Published by Elsevier in Molecular Therapy
- Vol. 31 (4) , 1046-1058
Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model
- 24 March 2023
- Published by Elsevier in Molecular Therapy
- Vol. 31 (4) , 1046-1058
Open AccessEvaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model
- Open Access
- 5 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (555)
An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates
Replicating RNA vaccine delivered by lipid inorganic nanoparticles induces neutralizing antibody and T cells against SARS-CoV-2 in mice and macaques.
- 5 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (555)
Open AccessAn Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates
Replicating RNA vaccine delivered by lipid inorganic nanoparticles induces neutralizing antibody and T cells against SARS-CoV-2 in mice and macaques.
- Open Access
Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates
The ongoing COVID-19 pandemic, caused by infection with SARS-CoV-2, is having a dramatic and deleterious impact on health services and the global economy. Grim public health statistics highlight the need for vaccines that can rapidly confer protection after a single dose and be manufactured using components suitable for scale-up and efficient distribution. In response, we have rapidly developed repRNA-CoV2S, a stable and highly immunogenic vaccine candidate comprised of an RNA replicon formulated with a novel Lipid InOrganic Nanoparticle (LION) designed to enhance vaccine stability, delivery and immunogenicity. We show that intramuscular injection of LION/repRNA-CoV2S elicits robust anti-SARS-CoV-2 spike protein IgG antibody isotypes indicative of a Type 1 T helper response as well as potent T cell responses in mice. Importantly, a single-dose administration in nonhuman primates elicited antibody responses that potently neutralized SARS-CoV-2. These data support further development of LION/repRNA-CoV2S as a vaccine candidate for prophylactic protection from SARS-CoV-2 infection.
Open AccessSingle-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates
The ongoing COVID-19 pandemic, caused by infection with SARS-CoV-2, is having a dramatic and deleterious impact on health services and the global economy. Grim public health statistics highlight the need for vaccines that can rapidly confer protection after a single dose and be manufactured using components suitable for scale-up and efficient distribution. In response, we have rapidly developed repRNA-CoV2S, a stable and highly immunogenic vaccine candidate comprised of an RNA replicon formulated with a novel Lipid InOrganic Nanoparticle (LION) designed to enhance vaccine stability, delivery and immunogenicity. We show that intramuscular injection of LION/repRNA-CoV2S elicits robust anti-SARS-CoV-2 spike protein IgG antibody isotypes indicative of a Type 1 T helper response as well as potent T cell responses in mice. Importantly, a single-dose administration in nonhuman primates elicited antibody responses that potently neutralized SARS-CoV-2. These data support further development of LION/repRNA-CoV2S as a vaccine candidate for prophylactic protection from SARS-CoV-2 infection.
- Open Access
Integrated technology platform for accelerated discovery of antiviral antibody therapeutics
The emergence and reemergence of highly virulent viral pathogens with pandemic potential has created an urgent need for accelerated discovery of antiviral therapeutics. Antiviral human monoclonal (mAbs) are promising drug candidates to prevent or treat severe viral diseases, but the long timelines needed for discovery limits their rapid deployment and use. Here, we report the development of an integrated sequence of technologies incorporating advances in single-cell mRNA sequence analysis, bioinformatics, synthetic biology, and high-throughput functional analysis that allowed us to discover highly potent antiviral human mAbs and validate their activity in vivo at an unprecedented scale, speed, and efficiency. In a 78-day study, modeling deployment of a rapid response platform to an outbreak, we isolated >100 individual Zika virus (ZIKV) specific human mAbs, assessed their function, identified 29 broadly-neutralizing mAbs, and verified therapeutic potency of lead candidates with antibody-encoding mRNA formulation and/or IgG protein delivery in mice and nonhuman primates. Our work provides a roadmap for the rapid antibody discovery programs against viral pathogens of global concern.
Open AccessIntegrated technology platform for accelerated discovery of antiviral antibody therapeutics
The emergence and reemergence of highly virulent viral pathogens with pandemic potential has created an urgent need for accelerated discovery of antiviral therapeutics. Antiviral human monoclonal (mAbs) are promising drug candidates to prevent or treat severe viral diseases, but the long timelines needed for discovery limits their rapid deployment and use. Here, we report the development of an integrated sequence of technologies incorporating advances in single-cell mRNA sequence analysis, bioinformatics, synthetic biology, and high-throughput functional analysis that allowed us to discover highly potent antiviral human mAbs and validate their activity in vivo at an unprecedented scale, speed, and efficiency. In a 78-day study, modeling deployment of a rapid response platform to an outbreak, we isolated >100 individual Zika virus (ZIKV) specific human mAbs, assessed their function, identified 29 broadly-neutralizing mAbs, and verified therapeutic potency of lead candidates with antibody-encoding mRNA formulation and/or IgG protein delivery in mice and nonhuman primates. Our work provides a roadmap for the rapid antibody discovery programs against viral pathogens of global concern.
- 3 January 2020
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (4) , 2515-2523
Physicochemical structure of a polyacrylic acid stabilized nanoparticle alum (nanoalum) adjuvant governs TH1 differentiation of CD4+ T cells
The growing shift to subunit antigen vaccines underscores the need for adjuvants that can enhance the magnitude and quality of immune response.
- 3 January 2020
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (4) , 2515-2523
Physicochemical structure of a polyacrylic acid stabilized nanoparticle alum (nanoalum) adjuvant governs TH1 differentiation of CD4+ T cells
The growing shift to subunit antigen vaccines underscores the need for adjuvants that can enhance the magnitude and quality of immune response.
- 2 July 2019
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Magnetics
- Vol. 55 (10) , 1-7
Micro-Traveling Wave Magnetic Particle Imaging—Sub-Millimeter Resolution With Optimized Tracer LS-008
Magnetic particle imaging (MPI) is a novel tomographic imaging method, which allows determining the distribution of superparamagnetic iron-oxide nanoparticles in three dimensions. So far, various MPI systems have been presented with each one emphasizing different scanner features such as large field of view (FOV) or high resolution. For imaging with both high resolution and a large FOV, the optimization and harmonization of hardware parameters as well as tracer material are key prerequisites. The traveling wave MPI (TWMPI) approach uses an array of electromagnets, which can provide a high magnetic field gradient for a high resolution as well as a mouse-sized FOV at the same time. In combination with the tracer LS-008, which is optimized for the MPI technique, a resolution in the sub-millimeter range can be achieved. In this paper, an optimized scanner is presented based on the TWMPI approach featuring a gradient strength up to almost 10 T/m in an FOV with a length of 45 mm providing a high resolution below 500 microns using the optimized LS-008 tracer.
- 2 July 2019
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Magnetics
- Vol. 55 (10) , 1-7
Micro-Traveling Wave Magnetic Particle Imaging—Sub-Millimeter Resolution With Optimized Tracer LS-008
Magnetic particle imaging (MPI) is a novel tomographic imaging method, which allows determining the distribution of superparamagnetic iron-oxide nanoparticles in three dimensions. So far, various MPI systems have been presented with each one emphasizing different scanner features such as large field of view (FOV) or high resolution. For imaging with both high resolution and a large FOV, the optimization and harmonization of hardware parameters as well as tracer material are key prerequisites. The traveling wave MPI (TWMPI) approach uses an array of electromagnets, which can provide a high magnetic field gradient for a high resolution as well as a mouse-sized FOV at the same time. In combination with the tracer LS-008, which is optimized for the MPI technique, a resolution in the sub-millimeter range can be achieved. In this paper, an optimized scanner is presented based on the TWMPI approach featuring a gradient strength up to almost 10 T/m in an FOV with a length of 45 mm providing a high resolution below 500 microns using the optimized LS-008 tracer.